126 related articles for article (PubMed ID: 11087042)
1. Effect of carbonate salts on the kinetics of acid-catalyzed dimerization of adefovir dipivoxil.
Yuan LC; Dahl TC; Oliyai R
Pharm Res; 2000 Sep; 17(9):1098-103. PubMed ID: 11087042
[TBL] [Abstract][Full Text] [Related]
2. Coformer selection based on degradation pathway of drugs: a case study of adefovir dipivoxil-saccharin and adefovir dipivoxil-nicotinamide cocrystals.
Gao Y; Gao J; Liu Z; Kan H; Zu H; Sun W; Zhang J; Qian S
Int J Pharm; 2012 Nov; 438(1-2):327-35. PubMed ID: 22989978
[TBL] [Abstract][Full Text] [Related]
3. [Compare the effect of combined therapy between telbivudine plus adefovir dipivoxil and lamivudine plus adefovir dipivoxil corresponding to renal function in patients with hepatitis B virus infection].
Xu J; Bao L; Wang Y; Yang L; Li WT; Zhao ZH; Li Y
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):288-293. PubMed ID: 29996341
[No Abstract] [Full Text] [Related]
4. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.
Westland CE; Yang H; Delaney WE; Gibbs CS; Miller MD; Wulfsohn M; Fry J; Brosgart CL; Xiong S;
Hepatology; 2003 Jul; 38(1):96-103. PubMed ID: 12829991
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and renal impairment.
Shiffman ML; Pol S; Rostaing L; Schiff E; Thabut D; Zeuzem S; Zong J; Frederick D; Rousseau F
J Clin Pharmacol; 2011 Sep; 51(9):1293-301. PubMed ID: 20978280
[TBL] [Abstract][Full Text] [Related]
6. Enhanced dissolution and stability of adefovir dipivoxil by cocrystal formation.
Gao Y; Zu H; Zhang J
J Pharm Pharmacol; 2011 Apr; 63(4):483-90. PubMed ID: 21401599
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Ion-pair Formation of Adefovir to Improve Permeation across Artificial and Biological Membranes.
Darsazan B; Shafaati A; Zarghi A; Mortazavi SA
J Pharm Pharm Sci; 2018; 21(1):160-170. PubMed ID: 29789103
[TBL] [Abstract][Full Text] [Related]
8. [Determination of adefovir dipivoxil and its degradation products by reversed-phase high performance liquid chromatography].
Jiang Y; Xu Z; Zhang X
Se Pu; 2004 May; 22(3):248-51. PubMed ID: 15712909
[TBL] [Abstract][Full Text] [Related]
9. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
Moon JH; Cho M; Yoon KT; Bae JH; Heo J; Kim GH; Kang DH; Song GA
Korean J Hepatol; 2008 Dec; 14(4):503-12. PubMed ID: 19119245
[TBL] [Abstract][Full Text] [Related]
10. Oral formulations of adefovir dipivoxil: in vitro dissolution and in vivo bioavailability in dogs.
Cundy KC; Sue IL; Visor GC; Marshburn J; Nakamura C; Lee WA; Shaw JP
J Pharm Sci; 1997 Dec; 86(12):1334-8. PubMed ID: 9423141
[TBL] [Abstract][Full Text] [Related]
11. Adefovir dipivoxil in chronic hepatitis B: history and current uses.
Segovia MC; Chacra W; Gordon SC
Expert Opin Pharmacother; 2012 Feb; 13(2):245-54. PubMed ID: 22242973
[TBL] [Abstract][Full Text] [Related]
12. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B.
Jonas MM; Kelly D; Pollack H; Mizerski J; Sorbel J; Frederick D; Mondou E; Rousseau F; Sokal E
Hepatology; 2008 Jun; 47(6):1863-71. PubMed ID: 18433023
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection.
Sokal EM; Kelly D; Wirth S; Mizerski J; Dhawan A; Frederick D
J Clin Pharmacol; 2008 Apr; 48(4):512-7. PubMed ID: 18276803
[TBL] [Abstract][Full Text] [Related]
14. Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil.
Chen CH; Wang JH; Lee CM; Hung CH; Hu TH; Wang JC; Lu SN; Changchien CS
Antivir Ther; 2006; 11(6):771-8. PubMed ID: 17310821
[TBL] [Abstract][Full Text] [Related]
15. Nephrotoxicity, including acquired Fanconi's syndrome, caused by adefovir dipivoxil - is there a safe dose?
Law ST; Li KK; Ho YY
J Clin Pharm Ther; 2012 Apr; 37(2):128-31. PubMed ID: 21714795
[TBL] [Abstract][Full Text] [Related]
16. Mechanism study on stability enhancement of adefovir dipivoxil by cocrystallization: Degradation kinetics and structure-stability correlation.
Lin RZ; Sun PJ; Tao Q; Yao J; Chen JM; Lu TB
Eur J Pharm Sci; 2016 Mar; 85():141-8. PubMed ID: 26462447
[TBL] [Abstract][Full Text] [Related]
17. [Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].
Xing J; Han T; Liu L; Li Y; Li J; Li Y; Xiao SX
Zhonghua Gan Zang Bing Za Zhi; 2011 Nov; 19(11):828-32. PubMed ID: 22433304
[TBL] [Abstract][Full Text] [Related]
18. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.
Lee YS; Suh DJ; Lim YS; Jung SW; Kim KM; Lee HC; Chung YH; Lee YS; Yoo W; Kim SO
Hepatology; 2006 Jun; 43(6):1385-91. PubMed ID: 16729316
[TBL] [Abstract][Full Text] [Related]
19. A novel baseline hepatitis B virus sequencing-based strategy for predicting adefovir antiviral response.
Wang YW; Shan X; Huang Y; Deng H; Huang WX; Zhang DZ; Chen J; Tang N; Shan YL; Guo JJ; Huang A
Infect Genet Evol; 2015 Jul; 33():269-76. PubMed ID: 25983054
[TBL] [Abstract][Full Text] [Related]
20. [Research on molecular mechanism of drug resistance of adefovir dipivoxil].
Dai J; Tang H
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2012 Feb; 29(1):184-7. PubMed ID: 22404035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
